EIF5: A Drug Target / Disease Biomarker (G1983)
EIF5: A Drug Target / Disease Biomarker
EIF5, also known as exenatide fusion interleukin-5 (IL-5), is a protein that is expressed in various tissues throughout the body, including the lungs, heart, kidneys, and intestines. It is a key regulator of inflammation and immune responses, and has been implicated in a number of diseases, including obesity, type 2 diabetes, and asthma.
One of the main functions of EIF5 is its role in the regulation of cytokine production. Cytokines are a type of protein that are secreted by immune cells in response to the presence of foreign substances in the body, such as bacteria or viruses. These cytokines play a crucial role in triggering an immune response and helping the body to fight off infections.
EIF5 is also involved in the regulation of inflammation in the body. When the body is exposed to an infection or injury, EIF5 helps to recruit and activate immune cells to fight off the invading microorganisms or damaged tissue. This process is essential for maintaining the health and function of the immune system.
In addition to its role in immune and inflammatory regulation, EIF5 has also been shown to have a number of potential therapeutic applications. For example, it has been shown to be effective in treating obesity by reducing the levels of cytokines in the body and improving the body's sensitivity to insulin.
EIF5 has also been shown to be effective in treating type 2 diabetes by improving the body's sensitivity to insulin and by promoting the growth of healthy muscle tissue. This may help to lower the risk of complications such as heart disease and stroke in people with type 2 diabetes.
In addition to its potential therapeutic applications, EIF5 is also a drug target for a number of pharmaceutical companies. Several companies are currently working on developing drugs that target EIF5 in order to treat a range of diseases, including obesity, type 2 diabetes, and asthma.
Overall, EIF5 is a protein that has the potential to be a valuable drug target or biomarker. Its role in immune and inflammatory regulation, as well as its potential therapeutic applications, make it an attractive target for research and development. Further studies are needed to fully understand the effects of EIF5 and to determine its potential as a drug.
Protein Name: Eukaryotic Translation Initiation Factor 5
Functions: Catalyzes the hydrolysis of GTP bound to the 40S ribosomal initiation complex (40S.mRNA.Met-tRNA[F].eIF-2.GTP) with the subsequent joining of a 60S ribosomal subunit resulting in the release of eIF-2 and the guanine nucleotide. The subsequent joining of a 60S ribosomal subunit results in the formation of a functional 80S initiation complex (80S.mRNA.Met-tRNA[F])
The "EIF5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EIF5 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
EIF5A | EIF5A2 | EIF5AL1 | EIF5B | EIF6 | EIPR1 | ELAC1 | ELAC2 | ELANE | ELAPOR1 | ELAPOR2 | Elastase | ELAVL1 | ELAVL2 | ELAVL3 | ELAVL4 | ELDR | ELF1 | ELF2 | ELF2P4 | ELF3 | ELF3-AS1 | ELF4 | ELF5 | ELFN1 | ELFN1-AS1 | ELFN2 | ELK1 | ELK2AP | ELK3 | ELK4 | ELL | ELL2 | ELL2P1 | ELL3 | ELMO1 | ELMO2 | ELMO3 | ELMOD1 | ELMOD2 | ELMOD3 | ELN | ELOA | ELOA-AS1 | ELOA2 | ELOA3BP | ELOA3DP | ELOA3P | ELOB | ELOC | ELOF1 | Elongation Factor 1 Complex | Elongation of very long chain fatty acids protein | Elongin (SIII) complex | ELOVL1 | ELOVL2 | ELOVL2-AS1 | ELOVL3 | ELOVL4 | ELOVL5 | ELOVL6 | ELOVL7 | ELP1 | ELP2 | ELP3 | ELP4 | ELP5 | ELP6 | ELSPBP1 | EMB | EMBP1 | EMC1 | EMC1-AS1 | EMC10 | EMC2 | EMC3 | EMC3-AS1 | EMC4 | EMC6 | EMC7 | EMC8 | EMC9 | EMCN | EMD | EME1 | EME2 | EMG1 | EMID1 | EMILIN1 | EMILIN2 | EML1 | EML2 | EML2-AS1 | EML3 | EML4 | EML4-AS1 | EML5 | EML6 | EMP1 | EMP2
